Successful rituximab treatment of TAFRO syndrome with pathological findings of glomerular endothelial damage

Clinical Nephrology. Case Studies
Yuhei NodaTomohiko Naruse

Abstract

Thrombocytopenia, anasarca, fever, renal insufficiency, and organomegaly constitute TAFRO syndrome, a variant of Castleman disease. We describe a patient with TAFRO syndrome who underwent renal biopsy. A 79-year-old woman was referred to us with fever and leg edema. She also had thrombocytopenia, pleural effusion, ascites, and acute kidney injury, and was admitted to our hospital. Her response to initial therapy with corticosteroid and cyclosporine was poor. Therefore, she received 4 doses of rituximab per week, which resulted in clinical improvement, including recovery of thrombocytopenia. A kidney biopsy thereafter showed diffuse, global glomerular endothelial injury indicating thrombotic microangiopathy (TMA). These findings suggested that TMA is associated with the thrombocytopenia and renal insufficiency of TAFRO syndrome.

Citations

Oct 19, 2019·BMC Nephrology·Yoshikuni NagayamaKatsuyuki Matsui
Nov 22, 2020·La Revue de médecine interne·J MaquetL Sailler
Oct 23, 2020·Modern Rheumatology Case Reports·Yuta YamaguchiAtsushi Kumanogoh

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
light microscopy
electron microscopy
Electron

Related Concepts

Related Feeds

Castleman Disease

Castleman disease is a rare disorder that involves an overgrowth of cells in the lymph nodes. Unicentric Castleman disease affects one lymph node, usually in the chest or abdomen. Multicentric Castleman disease affects multiple lymph nodes, commonly located in the neck, collarbone, underarm and groin areas. Discover the latest research on Castleman disease here.